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Abstract
Between 2002 and 2007, travel related cases of Shigella sonnei and S. flexneri in Alberta, Canada were acquired from
Central America, the Indian subcontinent and North America. Of this group, resistance to ciprofloxacin and nalidixic
acid was identified in isolates from patients who had travelled to the Indian subcontinent. This study provides a
Canadian perspective to a growing body of literature linking ciprofloxacin and nalidixic acid resistance to travel to
the Indian subcontinent.
Shigella is a common cause of diarrheal illness in North America with a rate of 2.0 per 100,000 in Canada [1] and a
rate of 3.2 per 100,000 in the United States [2,3]. Imported cases of Shigella infections have been reported in devel-
oped countries following travel to a foreign or developing country [4,5] and may be impacted by factors including
socio-economic factors [6], food distribution networks [5] and microbiologic factors [7]. Across multiple geographic
regions, high rates of antimicrobial resistance to multiple agents (e.g. sulfonamides, tetracycline, chloramphenicol,
ampicillin, and trimethoprim-sulfamethoxazole) have limited the choices for empiric antimicrobial therapy required
to manage Shigella infections and reduce fecal excretion of the bacteria [8-10] with descriptions of shifting species
dominance and changes in antimicrobial susceptibility [10,11]. Generally, Shigella flexneri and Shigella sonnei are the
dominant species and are heavily impacted by changes in antimicrobial susceptibility [12,13].
This study identifies the global regions associated with travel-related cases of S. flexneri and S. sonnei in Alberta,
Canada and compares antibiotic resistance patterns of these isolates for 2002 to 2007 inclusive.
Specimens collected 2002-2007 (inclusive) from S. flexneri and S. sonnei infections in Alberta, Canada were included
for study. Data collected at time of specimen submission included: date of specimen collection, outbreak associa-
tion if present, travel history and antibiogram (data source-ProvLab Information Systems; Communicable Disease
Report at Alberta Health and Wellness). Outbreaks were defined by public health officials as ≥ 2 epidemiologically
related cases. Each outbreak was assigned a unique incident number. Repeat isolates received within six months of
original case infections were excluded. Only one representative case for each outbreak was included, unless the
isolates had different antibiotic susceptibility patterns. Based on travel history the origin of an isolate was grouped
into corresponding regions and continents. Regions included in the study represented major travel destinations for
individuals living in Canada. Domestic exposures were defined as “travel within North America.”
Isolate confirmation
Presumptive Shigella isolates were confirmed using con-
ventional biochemical tests [14]. Serotyping was done
for S. flexneri and phagetyping was done for S. sonnei.
Serotyping was performed using commercially available
antisera (Denka Seiken USA Inc., Campbell, CA) for
S.flexneri and the following serotypes (STs) were deter-
mined: 1-4, 6, SH-101, SH-104, and variants × or y [14].
Phage typing was performed on S. sonnei isolates follow-
ing standard procedures at the National Microbiology
Laboratory in Winnipeg, Manitoba [15]. For 2002 and
2003, there were representative but fewer numbers of
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any medium, provided the original work is properly cited.isolates were available for testing. For example, in 2002
and 2003, only 24% and 58% of representative isolates
were available respectively. From 2004-2007, representa-
tive isolates for each case of infection were available for
susceptibility testing: 2004 (100%), 2005 (100%), 2006
(89%), 2007 (91%).
Susceptibility testing
Susceptibility testing was performed using Sensititre
panels (Trek Diagnostic Systems, Cleveland, OH) against
the following antimicrobial agents:
￿ amikacin (AMI)
￿ amoxicillin/clavulanic acid (AMC)
￿ ampicillin (AMP)
￿ cefoxitin (FOX)
￿ ceftiofur (TIO)
￿ ceftriaxone (AXO)
￿ chloramphenicol (CHL)
￿ ciprofloxacin (CIP)
￿ gentamicin (GEN)
￿ kanamycin (KAN)
￿ nalidixic acid (NAL)
￿ streptomycin (STR)
￿ tetracycline (TET)
￿ sulfisoxazole (SSS)
￿ trimethoprim/sulfamethoxazole (SXT)
The minimum inhibitory concentrations (MIC) and
breakpoints were determined in accordance with guide-
lines established by the Clinical and Laboratory Stan-
dards Institute (CLSI) [16,17].
Data analysis
GraphPad Prism 5 software (GraphPad Software, Inc. La
Jolla, CA) was used for statistical analysis.
Between 2002-2007, 578 Shigella isolates were
received and confirmed by ProvLab. The overall
Table 1 Travel history and frequency of antimicrobial resistance of Shigella isolates in Alberta, 2002-2007
A
North
America
Central
America
South
America
Africa Middle
East
Indian
subcontinent
Far East
Asia
Unknown Western
Hemisphere
Eastern
Hemisphere
Shigella flexneri N=1 4 N=5 3 N=6 N=2 7 N=2 N=3 7 N=8 N=1 7 N=7 3 N=7 4
n(%) n(%) n(%) n(%) n(%) n(%) n(%) n(%) n(%) n(%)
Streptomycin 7(50) 30(57) 3(50) 12(44) 2(100) 32(86) 6(75) 14(82) 40(55) 52(70)
Ampicillin 7(50) 39(74) 4(67) 22(81) 2(100) 23(62) 7(88) 14(82) 50(68) 54(73)
Trimethoprim-
sulfamethoxazole
7(50) 21(40) 3(50) 17(63) 2(100) 26(70) 6(75) 14(82) 31(42) 51(69)
Sulfisoxazole 7(50) 25(47) 3(50) 21(78) 2(100) 26(70) 8(100) 14(82) 35(48) 57(77)
Chloramphenicol 8(57) 35(66) 4(67) 22(81) 2(100) 24(65) 6(75) 12(71) 47(64) 54(73)
Ciprofloxacin 1(7) 0(0) 0(0) 0(0) 0(0) 7(19)
1 0(0) 0(0) 1(1) 7(9)
Nalidixic acid 1(7) 0(0) 0(0) 0(0) 0(0) 21(57) 0(0) 3(18) 1(1) 21(28)
Tetracycline 13(93) 51(96) 6(100) 25(93) 2(100) 37(100) 6(75) 17(100) 70(96) 70(95)
Shigella sonnei N = 35 N = 87 N = 14 N = 16 N = 2 N = 25 N = 12 N = 31 N = 136 N = 55
Gentamicin 0(0) 0(0) 1(7) 0(0) 0(0) 0(0) 0(0) 1(3) 1(1) 0(0)
Streptomycin 34(97) 71(82) 7(50) 16(100) 2(100) 24(96) 10(83) 25(81) 109(80) 52(95)
Ampicillin 8(23) 30(34) 9(64) 1(6) 0(0) 1(4) 2(17) 19(61) 47(35) 4(7)
Amoxicillin/
clavulanic acid
0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 1(3) 0(0) 0(0)
Ceftiofur 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 2(6) 0(0) 0(0)
Ceftriaxone 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 2(6) 0(0) 0(0)
Trimethoprim-
sulfamethoxazole
26(74) 62(71) 14(100) 16(100) 2(100) 24(96) 11(82) 19(61) 99(73) 53(96)
Sulfisoxazole 30(86) 64(74) 14(100) 15(94) 2(100) 25(100) 10(83) 24(77) 105(77) 52(95)
Chloramphenicol 1(3) 0(0) 8(57) 0(0) 0(0) 1(4) 1(8) 0(0) 9(7) 2(4)
Ciprofloxacin 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0)
Nalidixic acid 4(11) 4(5) 0(0) 0(0) 0(0) 20(80) 0(0) 5(16) 8(6) 20(36)
Tetracycline 23(66) 57(66) 7(50) 15(94) 2(100) 25(100) 9(75) 14(45) 91(67) 51(93)
AData for antimicrobial susceptible isolates are not shown.
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316); S. flexneri 33.9% (n = 196); S. boydii 7.6% (n = 44);
S. dysenteriae 3.8% (n = 22). Twenty nine S. flexneri and
79 S. sonnei were not archived (stored and cataloged);
three S. flexneri could not be cultured; 15 S. sonnei
belonged to four outbreaks and were removed as they
had the same antibiogram as the index isolate for each
outbreak (nine S. sonnei isolates in 2006 and six S. son-
nei isolates in 2007). All but four S. flexneri and S. son-
nei isolates were isolates from stool specimens; two S.
sonnei isolates from blood, and two S. flexneri isolates
were from blood and urine. Of the 386 S. flexneri and S.
sonnei isolates, 74.9% (n = 289) were associated with
international travel; 12.7% (n = 49) associated with
domestic exposure within North America; 12.4% (n =
48) unknown travel history or origin of acquisition.
Rate calculations from Alberta population data were
u t i l i z e dt oe n s u r en ob i a st os t u d y .T h ed a t as e tl a c k sa
true denominator for all specimens received and tested.
S. flexneri rates ranged from 0.70 to 1.21 per 100,000,
and S. sonnei rates ranged from 1.10 to 1.98 per 100,000
per annum. The majority of travel cases for S. flexneri
were from Central America (32.3% [53/164]), the Indian
subcontinent (22.6% [37/164]) and North America (8.5%
[14/164]). The majority of S. sonnei cases were from
Central America (39.2% [87/222]), North America
(15.8% [35/222]), and the Indian subcontinent (11.3%
[25/222]).
Of the 196 S. flexneri isolates, as described above 164
were available for analysis, while 29 were not archived
and 3 did not grow. The most common ST for S. flex-
neri was ST2 (37.8% [62/164]) with 40.3% (25/62) of the
ST2 isolates originating from Central America. Of the S.
flexneri isolates from the Indian subcontinent the two
most common STs were ST2 (40.5% [15/37]) and ST6
(35.1% [13/37]). The most common phage type for S.
sonnei was S1 (65.8% [146/222]) with (38.4% [56/146]of
S1 isolates from Central America.
Only 1.2% (n = 2) S. flexneri and 8.1% (n = 18) S. son-
nei isolates were pan-susceptible to all antibiotics tested.
All S. flexneri isolates were susceptible to AMI, GEN,
AMC, KAN, FOX, TIO, AXO. All the S. sonnei were
Table 2 Median MICs of antimicrobial agents in S. flexneri and S. sonnei per year
AMI AMP AMC AXO CHL CIP SXT FOX GEN KAN NAL SSS STR TET TIO
S.
flexneri
Total per year
(n)
2002 10 4 2 2 < =
0.25
0.5 < =
0.015
<=
0.12
21 < =
8
1 > 256 < =
32
>3 2 <=
0.12
2003 28 2 > 32 8 < =
0.25
>3 2 <=
0.015
> 4 2 0.5 < =
8
1 > 256 > 64 > 32 0.25
2004 38 2 > 32 8 < =
0.25
32 < =
0.015
> 4 2 0.5 < =
8
1 > 256 > 64 > 32 < =
0.12
2005 35 2 > 32 8 < =
0.25
>3 2 <=
0.015
> 4 4 0.5 < =
8
1 > 256 64 > 32 0.25
2006 22 2 > 32 8 < =
0.25
32 < =
0.015
0.25 2 0.5 < =
8
2 > 256 64 > 32 < =
0.12
2007 31 2 > 32 8 < =
0.25
32 < =
0.015
0.25 4 0.5 < =
8
2< =
16
64 > 32 < =
0.12
S. sonnei Total per year
(n)
2002 12 2 32 4 < =
0.25
4< =
0.015
>4 1 1 <=
8
1 > 256 > 64 > 32 0.25
2003 27 2 32 4 < =
0.25
4< =
0.015
>4 1 1 <=
8
1 > 256 > 64 > 32 0.25
2004 35 2 2 4 < =
0.25
4< =
0.015
> 4 1 0.5 < =
8
1 > 256 > 64 > 32 0.25
2005 60 2 2 4 < =
0.25
8< =
0.015
>4 2 1 <=
8
1 > 256 > 64 > 32 0.25
2006 26 2 2 2 < =
0.25
4< =
0.015
> 4 2 0.5 < =
8
1 > 256 > 64 > 32 0.25
2007 19 2 2 2 < =
0.25
4< =
0.015
> 4 2 0.5 < =
8
2 > 256 > 64 > 32 0.25
amikacin (AMI), amoxicillin/clavulanic acid (AMC), ampicillin (AMP), cefoxitin (FOX), ceftiofur (TIO), ceftriaxone (AXO), chloramphenicol (CHL), ciprofloxacin (CIP),
gentamicin (GEN), kanamycin (KAN), nalidixic acid (NAL), streptomycin (STR), tetracycline (TET), sulfisoxazole (SSS), trimethoprim/sulfamethoxazole (SXT).
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(Table 1).
When median MICs were analyzed for all agents the
following changes were identified as in Table 2. For S.
flexneri median MICs were within two dilutions for
most agents over the study period. Exceptions were for
the following agents; AMP (increase), CHL (increase),
SXT (increase and following drop), and SSS (decrease).
For S. sonnei, median MICs were within two dilutions
for most agents over the study period with the following
exceptions; exception of AMP (decrease).
When data was combined for all years, the NAL and
CIP resistance was 20.1% (33/164) and 14.9% (33/222)
for S. flexneri and S. sonnei respectively. CIP resistance
was identified only in S. flexneri isolates (4.9%, 8/164)
when averaged over the six-year study period (Fisher’s
exact test, p = 0.001) (Figure 1a and 1b) CIP resistance
in S. flexneri was not steady but instead was most evi-
dent in the years 2005, 2006, and 2007 (Figure 1a).
Combined CIP and NAL resistance was related to travel
to the Indian subcontinent for S. flexneri (84.8%, 28/37)
and S. sonnei (80.0%, 20/25) (Fisher’s exact test, p <
0.0001). The proportion of antibiotic resistance was con-
stant over six years except for S. sonnei,w h e r eA M P
resistance decreased from 83% in 2002 to 11% in 2007
(p < 0.0001, c
2 = 36.52, df = 5) and NAL resistance
increased from 0% in 2002 to 30% in 2007 (p = 0.0168,
c
2 = 13.82, df = 5).
Figure 1 Frequency of antimicrobial resistance of study isolates from Alberta 2002-2007: 1 a) S. flexneri (n = 164); and 1b) S. sonnei
(n = 222).
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Page 4 of 6At the study onset, treatment guidelines suggested a
fluoroquinolone for acute traveler’s diarrhea regardless of
travel location. It is possible that some CIP resistance
was underestimated in 2002-2003 due to the smaller
number of isolates tested. By 2009, treatment guidelines
for acute traveler’s diarrhea (outside of Latin America
and Africa) suggested azithromycin or a fluoroquinolone
[18,19]. Data also suggests that azithromycin resistance
may be emerging and resistance rates of 16% have been
recently described in Bangladesh [20]. These studies indi-
cate that travel to the Indian subcontinent, in patients
returning to Western Canada with traveler’s diarrhea
should be determined to guide initial empiric treatment
options; especially for severe infections because the asso-
ciation of S. flexneri and S. sonnei isolates from this
region with fluoroquinolone and potential macrolide
resistance [13,21]. Although CIP resistance was described
only in S. flexneri, we should remain vigilant for develop-
ing gyrA and parC mutations as well as the presence of
plasmid mediated quinolone resistance determinants
(PMQR) genes that may lead to increasing rates of CIP
resistance in travel-related Shigella isolates which are
beginning to emerge globally [4,22].
There are multiple factors that may have lead to CIP
and NAL resistance in Shigella species originating from
the Indian subcontinent [21]. It is possible that part of
this emerging resistance may be associated with the
increasing dominance of specific STs or clones of Shi-
gella. Both this study and other work have identified a
dominance of S. flexneri STs 2 and 6 in isolates of
Indian origin and cases of traveler’s diarrhea associated
with the Indian subcontinent [23]. One factor driving
multi-drug resistance in the Indian subcontinent may be
the emergence of specific clones within these dominant
STs [24]. Therefore, the identification of clonal groups
within Alberta strains may be a powerful tool for track-
ing the development of drug-resistance in Shigella iso-
lates from future cases of traveler’s diarrhea.
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